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a,b Saudi ArabiaBackground: Dyslipidemia, a known cardiovascular risk factor, is extremely common among Saudis, both adults and
children. The impact, however, of dyslipidemia and several other lipid disorders in patients with congestive heart
failure in this particular population has not been documented. This study aims to fill the gap.
Methods: This retrospective, single center study was conducted at King Abdulaziz Medical City, Riyadh, Saudi
Arabia. Of the 500 cases seen during the period between 2002 and 2008, 392 were included in the study. Charts were
reviewed and information on medical history, medications, and lipid status were documented.
Results: Low HDL-cholesterol level was the most common lipid disorder with 82.9%, followed by hypertriglyc-
eridemia (35.2%), atherogenic dyslipidemia (27.8%), and hypercholesterolemia (9.2%). Diabetes mellitus was the sin-
gle most significant predictor of mortality (p = 0.001). Among the lipid disorders, only low levels of HDL-cholesterol
contributed to significant mortality risk [OR 1.29 (Confidence Interval 1.04–1.59) (p-value < 0.01)] adjusted for age,
gender and statin use.
Conclusion: The results of this study suggest that emphasis should be on the elevation of HDL-cholesterol levels
among subjects with congestive heart failure, without compromising any ongoing management of LDL-lowering
drugs. Management should not be limited to conventional statin use and should promote other treatments to elevate
HDL-cholesterol levels.
 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Lipid disorders are considered major risk fac-tors for vascular diseases including coronary
heart diseases that account for the majority ofover-all cause mortality [1]. Furthermore, dyslipi-
demia, defined as having abnormal levels of circu-
lating lipids, is common even among apparently
healthy individuals with no manifestations of car-
diovascular disease [2]. While studies conductedNC-ND
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regards to dyslipidemia have only recently begun
to flourish, recent epidemiologic data reveal that
dyslipidemia is the most common cardiovascular
risk factor in both children [3] and adults [4], with
an estimated nine out of every 10 Saudis having
low levels of HDL-cholesterol. Despite these stag-
gering figures, however, the country has a
relatively low prevalence of coronary heart dis-
ease (age-adjusted prevalence of 6.9%) as com-
pared to other developed nations, and this is
primarily due to the relatively young population
in the kingdom [5]. Nevertheless, having the pre-
disposition to develop dyslipidemia, or any other
cardiovascular risk factors at an early age, may
potentially overwhelm the public health sector in
the long run if no aggressive interventions are car-
ried out. In fact, regional information, though
scarce, already reveals that people from Africa
and the Middle East present with myocardial
infarction at a relatively younger age when com-
pared to other ethnicities, and deaths attributed
to coronary artery diseases are projected to
increase at an overwhelming rate of 171% between
1990 and 2020 [6].
In the present single-center retrospective study,
and for the first time in the Saudi Arabian popula-
tion, we sought to determine which among the
commonly encountered lipid disorders (low
HDL-cholesterol, hypertriglyceridemia, hypercho-
lesterolemia and atherogenic dyslipidemia) pre-
dispose patients with established heart failure
(HF) to increased mortality. We also assessed the
prevalence of the various lipid disorders among
this population group.Table 1. General characteristics of patients.
N 392
Males 208 (53.1)
Age (years)# 67.77 (12.8)
Mortality 205 (52.3)
Hypertension 333 (84.9)
Low HDL-cholesterol 325 (82.9)
Hypertriglyceridemia 138 (35.2)
Hypercholesterolemia 36 (9.2)
Atherogenic dyslipidemia 109 (27.8)
Smokers 60 (15.3)
Diabetes mellitus type 2 (DMT2) 242 (61.7)
Valvular disease 45 (11.5)
Ischemic cardiomyopathy 268 (68.5)
Chronic atrial fibrillation 103 (26.3)
PTCA/CABG 91 (23.2)
Stroke/TIA 89 (22.7)
Note: Data presented as N (%); # denotes mean (standard deviation).Materials and methods
This single-center, retrospective study was con-
ducted at King Abdulaziz Medical City (KAMC),
Riyadh, KSA. The charts of 500 patients, admitted
secondary to HF [defined as systolic heart failure
or HF with reduced ejection fraction (EF) 640%)
and/or HF with preserved EF (EFP 50), [7] who
were diagnosed either clinically and/or by
echocardiogram and/or cardiac catheterization],
or who visited the out-patient department for
the same complaint between the years 2002 and
2008 were reviewed and screened for inclusion.
Cases were excluded if the HF was congenital in
origin, end-stage renal disease (ESRD), or if the
patient was above 90 years of age. From the roster
of cases, a total of 392 cases met the criteria for this
study. Information gathered included demo-
graphics, medical history, and medications taken.Laboratory results obtained during admission/e-
valuation were also obtained and included lipid
profiles. For the purpose of this study, atherogenic
dyslipidemia was defined as triglycerides
>1.69 mmol/l and either HDL <1.03 mmol/l (men)
or HDL <1.29 mmol/l (women) [8]. Hypercholes-
terolemia was defined as serum total cholesterol
concentration P5.18 mmol/l [9].
Data analysis
Raw data were encoded in MS Excel spread-
sheet. Data were analyzed using the Statistical
Package for the Social Sciences version 17.0 (SPSS,
Chicago, IL, USA). Frequencies were presented as
percentage (%). Odds ratio was obtained to
determine mortality risk among lipid disorders.
Multinomial logistic regression analysis was per-
formed using mortality as dependent variable
and all the categorical variables (medications as
confounders) measured as independent variables
to determine which among the diseases of interest
had the most significant impact in predicting mor-
tality in the cohort. Significance was set at p < 0.05.Results
Table 1 highlights the demographic characteris-
tics of the subjects. More than half of the subjects
included were men (53.1%) and the over-all mor-
tality was 52.3%. No significant difference was
observed between the mortality of males versus
females (p = 0.56). Among the diseases listed,
Table 2. Medications of subjects.
Medications
ACE I 175 (45.1)
ARB 135 (34.8)
b-Blockers 269 (69.3)
Diuretics 298 (76.8)
Spironolactone 88 (22.7)
Statins 273 (70.7)
Nitrates 52 (17.7)
Anti-arrhythmic 22 (5.7)
Digitalis 55 (14.2)
Aspirin 241 (62.3)
Warfarin 70 (18.1)
Plavix 85 (22.0)
CRT, ICD, combined 35 (9.0)
Note: Data presented as N (%).
Figure 1. Lowlevels of HDL-cholesterol contributed to significant
mortality risk.
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LIPID DISORDERS VERSUS MORTALITY IN PATIENTS WITH CHFhypertension was noted to be the most common
(84.9%) followed by ischemic cardiomyopathy
(68.5%) and DMT2 (61.7%). Among the lipid
disorders, low HDL-cholesterol level was the most
common lipid disorder with 82.9%, followed by
hypertriglyceridemia (35.2%), atherogenic dyslipi-
demia (27.8%) and hypercholesterolemia (9.2%).
Table 2 shows the medications used by the sub-
ject. Worthy of note is that 70% of the subjects
were on statin treatment. Table 3 shows the odds
ratio for the different diseases present in the
cohort in relation to mortality while adjusting for
age, gender, and medication use, and revealed
that diabetes mellitus is the single most significant
predictor for mortality (p = 0.001). Also worthy of
note, though not significant probably due to sam-
ple size, was low HDL-cholesterol which falls sec-
ond to DMT2 in terms of mortality risk (p = 0.11).
Fig. 1 reveals that among the four lipid disorders
described in the present study, only low levels of
HDL-cholesterol contributed to significant mor-
tality risk [OR 1.29 (Confidence Interval 1.04–
1.59)] (p-value < 0.01)] adjusted for age, gender,
and statin use.Table 3. Multi-logistic regression analysis using mortality as depen
Variables measured Coefficient b
Hypertension 0.80
Ischemia 0.001
PTC/CABG 0.22
Stroke 0.12
Diabetes mellitus 0.76
Hypercholesterolemia 0.16
Low HDL-cholesterol 0.63
Hypertriglyceridemia 0.16
Dyslipidemia 0.146
Note: Results were adjusted for gender and all the medications listed in TabDiscussion
The main findings in this study reveal that the
prevalence of lipid disorders remains high,
particularly low HDL-cholesterol levels, despite
the majority of subjects taking lipid-lowering
agents, and that DMT2 is the significant indepen-
dent predictor of mortality among Saudi patients
with congestive heart failure. The presence of
DMT2, which on its own is considered a vascular
disease, is a major cardiovascular risk factor and
is expected to remain significant even after adjust-
ment for all documented confounders. Notably,
more than 60% of the patients included harbor
DMT2, although hypertension was more common.
Furthermore, it has been well established from
population-based studies that decreased levels of
HDL-cholesterol are associated with increased
risk of cardiovascular morbidity and mortality
[10–14]. While the present study confirms adent variable.
Odds ratio 95% CI P-value
1.08 0.69–2.0 0.79
1.00 0.61–1.66 0.99
0.79 0.47–1.35 0.40
1.12 0.66–1.92 0.37
0.47 0.30–0.75 0.001
0.85 0.39–1.86 0.69
0.53 0.25–1.14 0.11
1.17 0.39–3.52 0.78
0.86 0.26–2.82 0.81
le 2. Significant at p < 0.05.
FU
LL LEN
G
TH
 A
RTIC
LE
94 AL QAHTANI ET AL
LIPID DISORDERS VERSUS MORTALITY IN PATIENTS WITH CHF
J Saudi Heart Assoc
2015;27:91–95plethora of scientific evidence with regards to
HDL-cholesterol and mortality, it also illustrates
that a very high incidence of dyslipidemia,
particularly low HDL-cholesterol, persists even
among patients already taking lipid-lowering
medication. As previously mentioned, epidemi-
ologic evidence already points to increased
incidence of low HDL-cholesterol even in an
apparently healthy population [3,4], and this inci-
dence remains true for the population used in this
study. The majority of the study subjects were on
statins, and while the major effect of the drug is on
total cholesterol, it exerts a minor yet significant
effect in elevating HDL-cholesterol levels, aside
from its conventional role of decreasing over-all
circulating cholesterol levels [15]. It was expected,
therefore, that the incidence of this type of lipid
disorder would be lower, yet the result was the
same when compared to the general population.
A low HDL-cholesterol level is one of the criteria
for metabolic syndrome. It has major vasoprotec-
tive and anti-inflammatory effects, while low
concentrations of HDL-cholesterol have been
associated with the development of atherosclerosis,
CVD, and decreased life expectancy [16]. Low
HDL-cholesterol is highly heritable in Saudi
families and begins to manifest as early as the
pre-teenage years [17]. Epidemiological studies
show there is a geographic prevalence gradient
with the lowest levels in Saudi Arabia, intermediate
levels in Asia Minor, and highest levels in western
Europe [18,19]. While information on the reasons
for the prevalence of depressed levels of HDL
cholesterol in the Saudi population is scarce,
several local interventional studies point to
improvement in circulating HDL-levels and other
cardiometabolic parameters after vitamin D
correction. Although vitamin D levels were not
assessed in the present study, it is interesting to
note that vitamin D deficiency is equally prevalent
in KSA [20–21]. The equally low levels of vitamin
D in the Saudi population may offer insights on
how to address the low levels of HDL-cholesterol,
aside from the use of conventional drugs.
The results of the present study have clinical
implications. First, clinical management should
include elevating/normalizing HDL-cholesterol
levels among subjects with HF, without compro-
mising existing management of LDL-lowering
drugs. There is a need to study HDL-cholesterol
in-depth in this particular population, as the
incidence of low HDL-cholesterol is not limited
to adults but is extremely high, even among
children. Furthermore, the consideration of ethnic
differences with a more tailored approach intreating Saudi patients with HF is an essential
undertaking.
The study has several limitations. Present find-
ings may not apply to other populations, as all
the subjects of the present study have HF. Fur-
thermore, the small sample size and the single-
center approach limit the findings of the study
and therefore cannot be generalized as applicable
to all patients with congestive heart failure unless
done on a larger scale. Nevertheless, this is the
first study to document the persistence of the
extremely high prevalence of low HDL-cholesterol
among Saudi patients with HF and on statins, as
well as the significant impact of DMT2 in con-
tributing to the over-all mortality rate of this
population. Management should not be limited
to conventional statin use and should promote
other treatments and non-pharmacological
options, such as vitamin D correction, that might
potentially elevate HDL-cholesterol levels.Disclosures
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